Shanghai Yuanwei Commercial Management Co., Ltd. – Trademark Portfolio

Entity Type: 99

Shanghai Yuanwei Commercial Management Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include BABZEN. The owner is based in Shanghai.

4881 Xinfeng Road, Fengxian District

Shanghai 200000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

BABZEN
BABZEN
Registered 2024

Trademark Classifications

Shanghai Yuanwei Commercial Management Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Shanghai Yuanwei Commercial Management Co., Ltd. have?

Shanghai Yuanwei Commercial Management Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shanghai Yuanwei Commercial Management Co., Ltd. file in?

Shanghai Yuanwei Commercial Management Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Shanghai Yuanwei Commercial Management Co., Ltd.'s most well-known trademarks?

Shanghai Yuanwei Commercial Management Co., Ltd.'s registered trademark portfolio includes well-known marks such as BABZEN. These are among 1 currently registered trademark in the portfolio.

What is Shanghai Yuanwei Commercial Management Co., Ltd.'s trademark registration success rate?

Shanghai Yuanwei Commercial Management Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.